- Home
- ALLO vs RCS Comparison
ALLO vs RCS Comparison
Compare ALLO & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- RCS
- Stock Information
- Founded
- ALLO 2017
- RCS 1994
- Country
- ALLO United States
- RCS United States
- Employees
- ALLO N/A
- RCS N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- RCS Investment Managers
- Sector
- ALLO Health Care
- RCS Finance
- Exchange
- ALLO Nasdaq
- RCS Nasdaq
- Market Cap
- ALLO 363.1M
- RCS 296.3M
- IPO Year
- ALLO 2018
- RCS N/A
- Fundamental
- Price
- ALLO $1.40
- RCS $7.06
- Analyst Decision
- ALLO Strong Buy
- RCS
- Analyst Count
- ALLO 9
- RCS 0
- Target Price
- ALLO $8.44
- RCS N/A
- AVG Volume (30 Days)
- ALLO 3.5M
- RCS 141.1K
- Earning Date
- ALLO 08-06-2025
- RCS 01-01-0001
- Dividend Yield
- ALLO N/A
- RCS 10.12%
- EPS Growth
- ALLO N/A
- RCS N/A
- EPS
- ALLO N/A
- RCS N/A
- Revenue
- ALLO N/A
- RCS N/A
- Revenue This Year
- ALLO N/A
- RCS N/A
- Revenue Next Year
- ALLO $199.63
- RCS N/A
- P/E Ratio
- ALLO N/A
- RCS N/A
- Revenue Growth
- ALLO N/A
- RCS N/A
- 52 Week Low
- ALLO $0.86
- RCS $4.51
- 52 Week High
- ALLO $3.78
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- ALLO 54.41
- RCS 61.93
- Support Level
- ALLO $1.21
- RCS $7.02
- Resistance Level
- ALLO $1.31
- RCS $7.16
- Average True Range (ATR)
- ALLO 0.11
- RCS 0.06
- MACD
- ALLO 0.02
- RCS -0.02
- Stochastic Oscillator
- ALLO 40.82
- RCS 52.38
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.